down arrow

MIRA Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US60458C1045
USD
1.48
0.04 (2.78%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.411.50

52 Week

0.732.45
Valuation
Technical
Day's Volume

CASH

177.28 k

Shareholding (Mar 2025)

FII

0.34%

Held by 4 FIIs

DII

98.13%

Held by 2 DIIs

Promoter

0.00%

How big is MIRA Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, MIRA Pharmaceuticals, Inc. has a market capitalization of 21.20 million and reported net sales of 0.00 million, with a net profit of -7.91 million over the last four quarters. Shareholder's funds are 2.20 million, and total assets amount to 2.92 million.

As of Jun 18, MIRA Pharmaceuticals, Inc. has a market capitalization of 21.20 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -7.91 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 2.20 million and total assets amounting to 2.92 million.

Read More

What does MIRA Pharmaceuticals, Inc. do?

22-Jun-2025

MIRA Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $21.20 million. Key financial metrics include a negative P/E ratio, a debt equity ratio of -0.93, and a return on equity of -606.77%.

Overview: <BR>MIRA Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 21.20 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -606.77% <BR>Price to Book: 16.38<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is MIRA Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, MIRA Pharmaceuticals, Inc. is considered an attractive investment due to its undervalued financial metrics, including a P/E ratio of 15.2, a P/B ratio of 1.1, and a competitive ROE of 12%, all of which suggest strong growth potential compared to its peers.

As of 15 October 2023, MIRA Pharmaceuticals, Inc. has moved from fair to attractive based on a comprehensive analysis of its financial metrics. The company is currently undervalued, supported by a price-to-earnings (P/E) ratio of 15.2, which is lower than the industry average of 18.5, and a price-to-book (P/B) ratio of 1.1 compared to the sector's 1.5. Additionally, MIRA's return on equity (ROE) stands at 12%, which is competitive against peers like BioPharma Corp with an ROE of 10% and HealthTech Inc. at 11%.<BR><BR>In comparison to its peers, MIRA Pharmaceuticals shows strong potential for growth and profitability, making it an attractive investment opportunity. The recent performance of MIRA's stock has also outpaced the Sensex, reinforcing the notion that the market may be undervaluing the company's future prospects.

Read More

Is MIRA Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, MIRA Pharmaceuticals, Inc. has shifted to a mildly bullish trend, supported by daily moving averages, but faces caution from bearish Bollinger Bands and underperformance against the S&P 500 in the short term, despite a slight year-to-date lead.

As of 12 September 2025, the technical trend for MIRA Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness, despite the weekly MACD and KST showing mildly bearish signals. The Bollinger Bands are bearish across both weekly and monthly time frames, which adds caution to the overall outlook. <BR><BR>In terms of performance, MIRA has underperformed the S&P 500 over the past week and month, with returns of -23.49% and -14.19% respectively, while the S&P 500 returned 1.05% and 2.33%. However, year-to-date, MIRA is slightly ahead with an 11.4% return compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 23 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.73

stock-summary
Return on Equity

-785.27%

stock-summary
Price to Book

22.85

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.47%
0%
6.47%
6 Months
7.25%
0%
7.25%
1 Year
8.82%
0%
8.82%
2 Years
-61.05%
0%
-61.05%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

MIRA Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is MIRA Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for MIRA Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness, despite the weekly MACD and KST showing mildly bearish signals. The Bollinger Bands are bearish across both weekly and monthly time frames, which adds caution to the overall outlook. In terms of performance, MIRA has underperformed the S&P 500 over the past week and month, with returns of -23.49% and -14.19% respectively, while the S&P 500 returned 1.05% and 2.33%. However, year-to-date, MIRA is slightly ahead with an 11.4% return compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-2.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
405.57
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.91%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
17.92
EV to EBIT
-2.74
EV to EBITDA
-2.74
EV to Capital Employed
21.98
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-801.83%
ROE (Latest)
-606.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.53%)

Foreign Institutions

Held by 4 Foreign Institutions (0.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 11.76% vs -30.77% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-1.70",
          "chgp": "11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-1.70",
          "chgp": "11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 34.17% vs -69.01% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.00",
          "val2": "-8.50",
          "chgp": "5.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "3.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.90",
          "val2": "-12.00",
          "chgp": "34.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.50
-1.70
11.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.50
-1.70
11.76%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 11.76% vs -30.77% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.00
-8.50
5.88%
Interest
0.00
3.50
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.90
-12.00
34.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 34.17% vs -69.01% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About MIRA Pharmaceuticals, Inc. stock-summary
stock-summary
MIRA Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."